Drugmakers will conduct lung-cancer trials under single protocol

06/12/2013 | Nature (free content)

A new project aims to create a "master protocol" that will involve multiple pharmaceutical companies using one experimental plan to test multiple lung-cancer treatments in hundreds of clinics throughout the US, speeding up the drug-approval process. The plan will match drugmakers with patients whose tumors are most genetically relevant to the tested treatments. "The drive is to make the whole process of personalized medicine more efficient," said Eric Rubin, vice president of oncology clinical research at Merck. If the project succeeds, it may be applied to additional cancers.

View Full Article in:

Nature (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD